Mirvetuximab Soravtansine API Manufacturer in India

Swapnroop Pharma · WHO-GMP Certified · +91 87670 62101

Mirvetuximab Soravtansine API

Mirvetuximab soravtansine is a folate receptor alpha (FRα)-directed antibody-drug conjugate (ADC) used in oncology. It combines an anti-FRα monoclonal antibody with the maytansinoid microtubule inhibitor DM4, connected through the cleavable linker sulfo-SPDB. The antibody targets FRα-expressing cancer cells, facilitating internalization and intracellular release of DM4, which disrupts microtubules and can lead to cell-cycle arrest and apoptotic cell death.

The FDA-approved product is mirvetuximab soravtansine-gynx (Elahere). In March 2024, the FDA granted regular approval for adults with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, with patient selection based on an FDA-approved test.

Mirvetuximab soravtansine is a complex biologic drug substance and should be characterized using appropriate ADC-specific analytical methods covering antibody identity, conjugation, drug-to-antibody ratio (DAR), purity, aggregates, free payload, linker-related impurities and biological activity.

Product Overview

Mirvetuximab soravtansine is an antibody-drug conjugate designed to selectively deliver a cytotoxic microtubule inhibitor to FRα-expressing cells.

The ADC contains three principal components:

  1. Anti-FRα monoclonal antibody
  2. DM4, a maytansine-derived microtubule inhibitor
  3. Sulfo-SPDB linker, which connects DM4 to the antibody

The FDA describes mirvetuximab soravtansine-gynx as a folate receptor alpha-directed antibody and microtubule inhibitor conjugate. The antibody component is produced using mammalian Chinese hamster ovary cells, while the small-molecule components are chemically synthesized.

The product has an approximate molecular weight of 150 kDa, with an average of 3.4 DM4 molecules attached per antibody molecule.

Key Features

  • Folate receptor alpha (FRα)-directed ADC
  • Oncology-focused biologic drug substance
  • Monoclonal antibody-based targeted delivery system
  • Contains DM4 microtubule inhibitor
  • Uses sulfo-SPDB linker technology
  • Average drug-to-antibody ratio (DAR): ~3.4
  • Approximate molecular weight: 150 kDa
  • Relevant to ovarian cancer therapy
  • Suitable for ADC analytical and pharmaceutical development
  • Requires specialized biologic and ADC characterization

Detailed Specifications

Parameter Specification
Appearance White crystalline powder or crystals
Identification IR & HPLC compliant
Assay (HPLC) 98.0% – 102.0%
Loss on Drying NMT 1.0%
Residue on Ignition NMT 0.5%
pH (1% Solution) Approximately 5.0
Individual Impurity NMT 0.5%
Total Impurities NMT 1.0%
Water Content NMT 1.0%
Get Bulk Quote via WhatsApp